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Abstract
Purpose: The purpose of this analysis was to identify key predictors which impact knowledge of
the Human Papillomavirus vaccine in adults aged 21 to 45 in Virginia.
Methods: Data was collected from the Together for Health Virginia Population Surveys
administered by Virginia Commonwealth University and the University of Virginia. Logistic
regression was performed on data using the variables sex, age, rurality, race, education, income,
occupation, and type of health insurance coverage.
Results: There was a statistically significant positive relationship between knowledge of the
HPV vaccine and part-time occupation (OR: 4.288, CI: 1.492-13.325), younger age (OR: 2.31,
CI: 1.088-4.905), and higher education (OR: 2.683, CI: 1.227-5.870). There was a statistically
significant negative relationship between knowledge of the vaccine and being male (OR: 0.437,
CI: 0.248-0.771), living in an urban area (OR: 0.511, CI: 0.267-0.977), and identifying in the
lower income category (OR: 0.246, CI: 0.093-0.651).
Conclusion: This study identified 6 key predictors in knowledge of the HPV vaccine among
adults in Virginia. Future studies should explore, in particular, the category of students and
residents of urban areas. Despite these results, knowledge of the HPV vaccine does not translate
to intention to receive the vaccine. Therefore, future studies should additionally study attitudes,
behaviors, and potential barriers.
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Background:
Human Papillomavirus (HPV) infects about 14 million people in the United States each
year, making it the most prevalent sexually transmitted disease in the country (Fueta & ChidoAmajuoyi, 2020). Although there are over 200 subtypes of the virus, 14 types are responsible for
5% to 10% of all cancers. Of these 14 subtypes, strains 16 and 18 are considered the most
oncogenic (Lehtinen & Dillner, 2013). It is estimated that over 90% of cervical and anal cancers,
75% of vaginal cancers, and 70% of oropharyngeal and vulvar cancers are caused by HPV.
Large percentages of penile (63%), oral (32%), and laryngeal (21%) cancers are also caused by
the virus (Saraiya et al., 2015). It is estimated that in 2021 alone, over 4,000 women will die
from cervical cancer in the United States (American Cancer Society, 2021). In addition to the
high rates of morbidity and mortality due to HPV-derived cancers, are the staggering economic
costs. According to the President’s Cancer Panel Annual Report from 2012 to 2013, the annual
economic burden stands at approximately $8 billion in the United States (Chesson et al., 2012).
These human and financial costs can be reduced by preventing HPV infections.
The HPV vaccine is an extremely effective preventative measure against the most cancerrelated strains. The most commonly heard of vaccine is Gardasil by Merck. Originally
quadrivalent protecting against only HPV 6/11/16/18, the nonvalent Gardasil9 vaccine protects
against HPV 6/11/16/18/31/33/45/52/58 (Gardasil, 2021). As of 2020, Gardasil9 is the only
vaccine being used in the United States (Saslow et al., 2020). There are two doses given at
various monthly intervals depending on if the vaccine recipient is younger or older than 15. The
vaccine is aimed at those aged 9 to 14 because they are less effective after commencement of
sexual intercourse and potential exposure to HPV. In trial, the nonvalent Gardasil9 vaccine was
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found to be as effective at preventing HPV 6/11/16/18 when compared to the quadrivalent
vaccine, but is also protective against HPV 31/33/45/52/58 (Joura et al., 2015).
Despite this convenient and effective vaccine, the United States is well below vaccinating the
Healthy People 2020 target of 80% of females aged 13 to 15. Utilizing data from 2008-2018,
only 48.9% and 47.1% of females and males, respectively, aged 13 to 15 had received 2 or 3
doses. When considering 13 to 17-year old’s, only 53.7% and 48.7% of females and males,
respectively, were vaccinated (HPV Vaccination, 2021). In the state of Virginia, rates for up to
date HPV vaccines for females and males 13 to 17 in 2016 were 41.1% and 37.4%, respectively.
50.7% and 56.4% of females and males 13 to 17, respectively, received one or more doses
(Walker, 2017). While higher than the national average for one or more doses, Virginia is still
well below vaccination rates necessary for herd immunity. Interestingly, Virginia was the first
state to mandate three doses of the HPV for adolescent girls entering middle school in 2008
(expanded to adolescent boys as of 2020) (§ 32.1-46). However, the bill included an opt-out
option if parents read educational materials on HPV. The rates in the years following the new
law indicate that the mandate was not effective. One difference-in-differences study found that
controlling for demographic factors, females in Virginia were less likely to be vaccinated when
compared to South Carolina and Tennessee, control states that did not have an HPV vaccine
school mandate (Pierre-Victor et al., 2017).
Why are vaccination rates so low? Why do mandates prove to be ineffective? There are a
multitude of factors that have been researched such as costs and access, scrutiny over an STDpreventing vaccine, and lack of education. The HPV vaccine requires three doses given months
apart. The vaccine cost is usually not a problem as most children are covered through private
insurance and public programs. Many childhood vaccine organizations cover uninsured,
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Medicaid eligible, Native American and Alaskan Native children (North & Niccolai, 2016).
However, there are other costs including transportation and taking time off work to accompany
children to appointments, especially in rural regions. For example, one study found that in
Kentucky, women in rural areas were 7 times less likely to receive their follow-up vaccine doses
compared to women living in urban areas (Crosby et al., 2011). In Virginia, 46% of counties are
rural and 72% are medically underserved, highlighting access due to geographic location as a
potential predictor for low vaccination rates (HRSA, 2017).
A second major reason for low vaccination rates for HPV is because it is perceived as the
“sex vaccine” and that vaccinating their children will increase risky sexual behaviors. However,
it was found that HPV vaccination status is not associated with earlier sexual behavior nor an
increased number of sexual partners (Brouwer et al., 2019). Further, by mandating vaccination in
Virginia, parents distrusted the vaccine more due to “perceived political involvement” (Pitts &
Tufts, 2013). Another study found that 23% of parents in the United States were hesitant due to
concern about side effects and the novelty of the vaccine (Szilagyi, 2020). Ultimately, this
barrier boils down to lack of knowledge. One study found that that 60.1% and 31.6% of men and
women, respectively, aged 18 to 26 years old did not know that HPV causes cervical cancer. Of
US adults, over 70% did not know HPV can cause anal, penile or oral cancers (Suk et al., 2019).
Even among survivors of HPV-related cancers, it was found that only 33.2% knew that their
cancer was caused by HPV and less than 60% felt that the HPV vaccine was safe (Shelal et al.,
2019).
These numbers are alarming and more research is warranted in order to improve
vaccination rates. While there are studies exploring HPV vaccination rates in Virginia, there is
data lacking on predictors of HPV vaccine knowledge throughout the state. This paper explores
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the role of sex, race, age, geographic setting (rural or metropolitan), education level, income,
occupation status, and health insurance type on if one has heard of the HPV vaccine in Virginia.

Methods:
Data analyzed in this study are from the Together for Health Virginia Population Health
Survey administered by the Virginia Commonwealth University (VCU) and the University of
Virginia (UVA). The purpose of this survey was to obtain state-level data on cancer-related
beliefs, attitudes, behaviors, and information sources. Virginia counties within the cancer center
catchment boundaries of the two universities were targeted (Appendix A). Survey data collection
was approved by the Institutional Review Board (IRB) at both universities. Sex, age, Black race
indicator, rurality, and HPV vaccine knowledge are dichotomized variables. Existing education,
income, occupation, and insurance categories from the survey were combined. The category
“Other” in Occupation includes the smallest categories: those who are disabled (4.52%), students
(2.02%), homemakers or stay-at-home parents (4.91%) and those categorized as “other” in the
original survey (1.25%). The category “Other” in health insurance similarly combined the
smallest categories: Alaska Native, Indian, and Tribal health services (0.29%), TRICARE
(4.56%), purchased health coverage on one’s own (4.06%), “some other source” (1.61%), and no
coverage (1.56%). Multivariate analysis was performed using SAS. Univariate analysis can be
found in Appendix B.
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Results:
Table 1: Demographic Characteristics of Survey Participants
Characteristic

Percent

Confidence Interval

Sex (n=1496)
Male
Female

47.91%
52.09%

43.49% - 52.34%
47.66% - 56.51%

Age (n=1496)
21 to 45 years old
45≤ years old

47.98%
52.02%

43.49%-52.47%
47.53% - 56.51%

Black (n=1496)
Yes
No

18.83%
81.17%

14.95%-22.71%
77.29%-85.05%

Rurality (n=1496)
Urban
Rural

33.74%
66.26%

29.66%-37.83%
62.17%-70.34%

Education (n=1427)
Not completed high school
High school or some college
College or Graduate School

7.72%
60.83%
31.45%

5.19%-10.25%
56.58%-65.08%
27.58%-35.32%

Individual Income (n=1193)
Less than 35k
35k to 49,999
50k to 99,999
100k+

32.01%
12.64%
29.13%
26.21%

27.00%-37.03%
9.57%-15.71%
24.70%-33.57%
22.36%-30.06%

Occupation (n=900)
Full-time
Part-time
Retired
Other

51.40%
8.53%
22.21%
17.86%

45.72%-57.09%
5.13%-11.92%
18.07%-26.36%
13.21%-22.50%

Health Insurance (n=1363)
Employer
Medicare
Medicaid
Other

52.43%
22.40%
13.09%
12.08%

47.79%-57.06%
18.84%-25.95%
9.14%-17.04%
9.36%-14.82%

Heard of HPV Vaccine
(n=1436)
Yes
No

72.26%
27.74%

68.26%-76.25%
23.75%-31.73%
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The distributions of sex and age were about even between men and women and those 21 to 45
and 45 and older. Most participants were not Black (81.17%), had completed high school or
some college (60.83%), worked full time (51.40%), had employer sponsored health insurance
(52.43%) and lived in a rural area (66.26%) (Table 1). Rurality in this survey was defined using
the U.S. Department of Agriculture, Economic Research Service (ERS) rural-urban continuum
codes. Metro or Urban Counties were coded 1 to 3. Nonmetro or Rural counties are coded 4 to 9
(USDA ERS, 2020). The income distribution was more evenly divided with a slight majority
(31.01%) having an income less than $35,000 (Table 1).
Because the predictors included in our model are conceptually related, correlations were
run between each variable to examine the possibility of multicollinearity. All correlations had
Pearson Correlation Coefficients below 0.36679 except for education and income which had a
value of 0.50511 (Appendix C). For this reason, regression was run twice, including and
excluding income as a predictor.
Knowledge of the HPV vaccine was the primary dependent variable in this model. The
survey read: “A vaccine to prevent HPV prevention is available and is called the HPV shot,
cervical cancer vaccine, GARDASIL, or Ceravix. Before today, have you ever heard of the HPV
vaccine?” The answer choices were “Yes” or “No.”
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Table 2: Logistic Regression: Modeling knowledge of the HPV vaccine based on sex, age,
education level, income, rurality, insurance type
Parameter
Intercept
Male
21-45 years old
Black
Urban
Education
<high school

Model 1: Including Income
Estimate
Odds Ratio
1.4932***
(0.3784)
-0.8273**
0.437
(0.2886)
(0.248-0.771)
0.8373*
2.310
(0.3835)
(1.088-4.905)
-0.4867
0.615
(0.6378)
(0.176-2.150)
-0.6712*
0.511
(0.3299)
(0.267-0.977)

Model 2: Excluding Income
Estimate
Odds Ratio
1.0441**
(0.3356)
-0.6214*
0.537
(0.2565)
(0.325-0.889)
0.8126*
2.254
(0.3263)
(1.188-4.276)
-0.4705
0.625
(0.4282)
(0.270-1.448)
-0.3928
0.675
(0.2816)
(0.389-1.173)

-0.7512
(0.5892)

0.472
(0.148-1.500)

-1.0698
(0.6024)

0.343
(0.105-1.119)

0.9871*
(0.3987)

2.683
(1.227-5.870)

0.7488*
(0.2985)

2.115
(1.177-3.799)

-0.5285
(0.4911)

0.589
(0.225-1.546)

-

-

-1.4009**
(0.4947)

0.246
(0.093-0.651)

-

-

-0.0805
(0.4948)

0.923
(0.349-2.438)

-

-

1.4559**
(0.5377)

4.288
(1.492-13.325)

1.4262*
(0.4964)

4.163
(1.571-11.028)

Retired

0.6770
(0.4069)

1.968
(0.885-4.375)

0.5093
(0.3586)

1.664
(0.823-3.364)

Other

0.5489
(0.5549)

1.731
(0.582-5.147)

0.6373
(0.4555)

1.891
(0.774-4.624)

-0.6317
(0.4321)

0.532
(0.228-1.242)

-1.0616*
(0.3850)

0.346
(0.162-0.736)

Medicaid

0.2497
(0.5571)

1.284
(0.430-3.833)

-0.2684
(0.4850)

0.765
(0.295-1.981)

Other

-0.1826
(0.4593)

0.833
(0.338-2.053)

-0.7333
(0.4550)

0.480
(0.198-1.163)

College or Graduate
School
ref= completed high
school/some college
Income
Less than 35k

35k to 49,999

100k+
ref= 50k to 99,999
Occupation
Part-Time

ref=Full-Time
Health Insurance
Medicare

Ref=Employer
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SE for Estimate and 95% Confidence Interval for Odds Ratio in Parentheses; *p<0.05; **p<0.01;
***p<0.0001
Given the large sample size, relatively low correlation coefficient (0.50511), and
similarities between models, analysis in this paper will consider the model which includes
income as a predictor for knowledge of the HPV vaccine (Table 2). There are 6 significant
predictors in this model. Being male, living in an urban area, or having an income from $35,000
to $49,999 relative to an income of $50,000 to $99,999 substantially decreased the odds that an
individual has knowledge of the HPV vaccine. Compared to females, the odds that males have
knowledge of the HPV vaccine are 0.437 times less (CI: 0.248-0.771). Similarly, those living in
an urban area are 0.511 times (CI: 0.267-0.977) less likely to have heard of the HPV vaccine.
Compared, to those who make $50,000 to $99,9999, those who fall into the bracket of $35,000 to
$49,999 were almost 0.246 times (CI: 0.093-0.651) less likely to have heard of the vaccine.
On the other hand, increased education – those with a college or graduate school degree were
2.683 times (CI: 1.227-5.870) more likely to have reported that they had knowledge of the HPV
vaccine compared to someone with, at minimum, a high school degree. Those who self-identified
as “Part-Time” were over 4 times as likely to have knowledge of the HPV vaccine compared to
“Full-Time” workers (OR: 4.288, CI: 1.492-13.325).

Discussion:
While there is evidence that rurality is associated with decreased HPV vaccination rates,
this study found that there was less knowledge of the HPV vaccine in urban areas (Crosby et al.,
2011). Given that this analysis did not control for cost of living in addition to income, this study
is limited in understanding the real-life financial situations of survey participants. According to
the US Census Bureau, 42 out of 50 states have higher poverty rates in urban versus rural areas.
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Poverty, which is tied to health literacy, could explain the lower rates of HPV vaccine
knowledge in urban areas. Additionally, 2010 census data indicates that rural communities are,
on average, comprised of 78% white, non-Hispanic individuals. Urban areas are nearly 15%
more racially diverse. Studies have consistently found disparities in health knowledge by race.
For example, one study found Hispanic and Black women were significantly less likely to have
heard of HPV compared to white women (Gelman et al, 2011). Given this existing literature, the
result of having less HPV vaccine knowledge in urban areas can be understood.
Interestingly those who were part of the $35,000 to $49,999 income range, but not those
who make less than $35,000, had significantly lower odds of having heard of the vaccine
compared to the $50,000 to $99,999 range. This could potentially be explained by the “PartTime” occupation being a significant predictor for having heard of the HPV vaccine. One
possible explanation is that, while the “Other” category contained an option for students, there is
a possibility that a disproportionate number of students in higher education self-identified as
“Part-Time.” As previously shown, increased education was associated with 3-fold higher odds
of having heard of the vaccine and would translate to part-time working students also having a
greater knowledge.
There are some limitations with this data. The survey was completed by a
disproportionate number of younger, affluent, and well-educated volunteers, limiting the
generalizability of the survey results. Additionally, many survey answers that are normally
continuous were binned into categories, limiting this study’s statistical ability to evaluate
variables such as age and income.
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Conclusion:
This study examined the relationship between knowledge of the HPV vaccine with race,
sex, age, rurality, education, income, occupation, and insurance coverage in the state of Virginia.
Knowledge is only the first step to increasing HPV vaccination rates. Although this survey
indicated that 72.26% of participants have heard of the HPV vaccine, this does not translate to
intention to receive it or to vaccinate their children and family members (Table 1).
Results indicated particular knowledge disparities by sex, age, rurality, income, and education.
Future studies focusing on these factors should be conducted to elucidate barriers to knowledge
to inform new policy. Increased knowledge and use of the HPV vaccine is crucial in reducing the
spread of the virus and associated cancer risk.
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Appendix A: Catchment Area Counties by University

Appendix B: Regression coefficients of Univariate Analysis for each predictor variable on
outcome
Male

Age 2145

Black

Urban

-0.7042***
(0.2066)

0.7393**
(0.2257)

-0.4937 -0.1566
(0.2725) (0.2091)

Education

Income

Occupation

Health
Insurance

Less than high
school:
-1.3559***
(0.3748)
College or
Graduate
school:
0.5701**
(0.2193)

<$35k:
-0.6157*
(0.3069)
$35k-$49:
-1.0047**
(0.3507)
$100k+:
0.3925
(0.3167)

Part-Time:
0.6915
(0.4657)
Other:
-0.0635
(0.3609)
Retired:
-0.6059*
(0.2973)

Medicare:
-0.8645***
(0.2471)
Medicaid:
-0.4263
(0.3975)
Other:
-0.9278**
(0.3111)

SE in parentheses; *p<0.05, **p<0.01, ***p<0.001
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Appendix C: Correlation Matrix
Sex

Sex

Age 2145

Black

Urban

Education

Income

Occupation

Health
Insurance

-0.04610

0.06804

0.0662

-0.01559

-0.17531

0.01318

-0.05291

-0.01902

0.02853

-0.09072

-0.05601

0.34023

0.14513

-0.14817

-0.13600

-0.20502

-0.05393

0.03168

0.05322

0.03548

0.05226

-0.01109

0.50511

-0.20327

-0.23243

-0.32420

-0.37107

Age 21-45

-0.04610

Black

0.06804

-0.01902

Urban

0.06662

0.02853

-0.14817

Education

-0.01559

-0.09072

-0.13600

0.05322

Income

-0.17531

-0.05601

-0.20502

0.03548

0.50511

Occupation

0.01318

0.34023

-0.05393

0.05226

-0.20327

-0.32420

Health
Insurance

-0.05291

0.14513

0.03168

-0.01109

-0.23243

-0.37107

0.36679
0.36679
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